Vet Med - Czech, 2017, 62(9):493-507 | DOI: 10.17221/65/2017-VETMED

Influence of new ultra-short-acting β-blockers on selected physiological indicators in laboratory ratsOriginal Paper

O. Bado*, M. Dlouha, E. Kolmanova, M. Frydrych
Faculty of Pharmacy, University of Veterinary and Pharmaceutical Sciences, Brno, Czech Republic

High rates of cardiovascular mortality have long been a serious problem in all European countries. Despite advancements in health care the situation is not improving fast enough. In the last decades, no new ultra-short-acting β-blockers have been registered in the European Union except for esmolol and landionol. In this study, eight newly-synthesised ultra-short-acting β-blockers were tested. These β-blockers contain an ester functional group which can be easily cleaved by plasma or cytoplasmic esterases. The substances were prepared in the Department of Chemical Drugs, Faculty of Pharmacy, University of Veterinary and Pharmaceutical Sciences, Brno. Systolic blood pressure, heart rate and the interval of the QRS complex were evaluated using normotensive laboratory Wistar rats. The tested compounds were administered intravenously into the vena jugularis during general anaesthesia. The arteria carotis was exposed and cannulated to a Universal Perfusion System Basic Unit (UPSBU) of type Uniper UP-100. The universal perfusion system for isolated organs was capable of measuring and transducing actual values of blood pressure. ECG records were made using the ECG SEIVA - Praktik Veterinary. A series of substances named 2FC2a, 2FC2b, 2FC2c, 2FC2d, and another series with substances named 2FT2a, 2FT2b, 2FT2c, 2FT2d were tested at a dose of 3 mg/kg. Results were statistically compared to placebo. The best results were obtained for propyl and butyl derivatives with the highest lipophilicity. These acted as the best blood pressure reducers immediately after their administration. None of the compounds notably affected the heart rate. Statistical data show that carbamate substitution considerably prolongated the duration of the QRS complex as compared to placebo or etheric substitution. The carbamate substitution caused a pronounced arrhythmogenic effect. Thus, we could confirm the short-term hypotensive effect of the compounds. We observed an effect on the electrical conduction system of the heart while no effects were observed on heart rate. Our study contributes to better describing potential new ultra-short-acting β-blockers and facilitates selection for further testing.

Keywords: ultra-short-acting β-blocker; laboratory rat; systolic blood pressure; heart rate; QRS complex

Published: September 30, 2017  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Bado O, Dlouha M, Kolmanova E, Frydrych M. Influence of new ultra-short-acting β-blockers on selected physiological indicators in laboratory rats. Vet Med - Czech. 2017;62(9):493-507. doi: 10.17221/65/2017-VETMED.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Atarashi H, Kuruma A, Yashima M, Saitoh H, Ino T, Endoh Y, Hayakawa H (2000): Pharmacokinetics of landiolol hydrochloride, a new ultra-short acting beta-blocker, in patients with cardiac arrhythmias. Clinical Pharmacology and Therapeutics 68, 143-150. Go to original source... Go to PubMed...
    2. Bado O (2009): Testing of antihypertensive activity of R isomer of compound 444 (in Slovak). [MSc Thesis.] VFU Brno, Pharmaceutical faculty, Czech Republic. Available at https://stagweb.vfu.cz/portal/studium/prohlizeni.html (Accessed October 23, 2015).
    3. Bado O, Frydrych M, Kolmanova E, Dlouha M (2014): In vivo testing of new ultrashort-acting beta-blockers with the effect on systolic blood pressure and heart rate (in Slovak). Ceska a Slovenska Farmacie 63, 167-173. Go to original source...
    4. Bakker EJ, Ravensbergen NJ, Voute MT, Hoeks SE, Chonchol M, Klimek M, Poldermans D (2011): A randomised study of perioperative esmolol infusion for haemodynamic stability during major vascular surgery; rationale and design of DECREASE-XIII. European Journal of Vascular and Endovascular Surgery 42, 317-323. Go to original source... Go to PubMed...
    5. Bartosova L, Frydrych M, Hulakova G, Berankova K, Strnadova V, Mokry P, Brunclik V, Kolevska J, Bebarova M (2004a): Efficacy of newly synthesized 44Bu ultrashortacting beta-adrenergic antagonist to isoprenaline-induced tachycardia - comparison with esmolol. Acta Veterinaria Brno 73, 171-179. Go to original source...
    6. Bartosova L, Frydrych M, Mokry P, Brunclik V, Bahnikova M (2004b): Testing of bradycardic effect of newly syntetised potencial ultrashort acting beta blockers on a laboratory rat (in Czech). Ceska a Slovenska Farmacie 53, 80-84.
    7. Bartosova L, Berankova K, Frydrych M, Opatrilova R, Strnadova V, Suchy P (2008): Stereoisomerism and pharmacological effects of newly synthesized drugs (in Czech). Chemicke Listy 102, 179-264.
    8. Basgut B, Kayki G, Bartosova L, Ozakca I, Seymen A, Kandilci H, Ugur M, Turan B, Ozcelikay T (2010): Cardioprotective effects of 44Bu, a newly synthesized compound, in rat heart subjected to ischemia/reperfusion injury. European Journal of Pharmacology 640, 117-123. Go to original source... Go to PubMed...
    9. Brunton LL, Lazo JS, Parker KL (2006): Goodman and Gilman's the Pharmacological Basis of Therapeutics. 11th edn. McGraw-Hill, New York. 491-542. Go to original source...
    10. Cizmarikova R (2002): β-adrenergic receptor blockers - a group of chiral drugs: differential effect of individual enantiomers (in Czech). Ceska a Slovenska Farmacie 51, 121-128.
    11. Cuneo BF, Zales VR, Blahunka PC, Benson Jr DW (1994): Pharmacodynamics and pharmacokinetics of esmolol, a short-acting beta-blocking agent, in children. Pediatric Cardiology 15, 296-301. Go to original source... Go to PubMed...
    12. Duricova J, Grundmann M (2009): Beta-blockers (in Czech). Ceska a Slovenska Farmacie 58, 60-66.
    13. Fowler MB (2008): Hypertension, heart failure, and betaadrenergic blocking drugs. Journal of the American College of Cardiology 52, 1073-1075. Go to original source... Go to PubMed...
    14. Frishman WH (2008): β-adrenergic blockers: A 50-year historical perspective. American Journal of Therapeutics 15, 565-576.
    15. Frishman WH (2011): Alpha- and beta-adrenergic blocking drugs. In: Frishman WH, Sica DA (eds): Cardiovascular Pharmacotherapeutics. 3rd edn. Cardiotext Inc, Minneapolis. 57-86.
    16. Frydrych M, Bartosova L, Florian T, Necas J, Bartosikova L, Kramar J, Mokry P, Brunclik V (2004): Influence of new ultrashort-acting beta-adrenergic blockers on systolic blood pressure in rats. Acta Veterinaria Brno 73, 181-185. Go to original source...
    17. Fumagalli L, Bolchi C, Colleoni S, Gobbi M, Moroni B, Pallavicini M, Pedretti A, Villa L, Vistoli G, Valoti E (2005): QSAR study for a novel series of ortho monosubstituted phenoxy analogues of alpha1-adrenoreceptor antagonist WB4101. Bioorganic and Medicinal Chemistry 13, 2547- 2559. Go to original source... Go to PubMed...
    18. Gorczynski RJ (1985): Basic pharmacology of esmolol. American Journal of Cardiology 56, 3-13. Go to original source... Go to PubMed...
    19. Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R, Dallongeville J, De Backer G, Ebrahim S, Gjelsvik B, Herrmann-Lingen C, Hoes A, Humphries S, Knapton M, Perk J, Priori SG, Pyorala K, Reiner Z, Ruilope L, Sans-Menendez S, Scholte op Reimer W, Weissberg P, Wood D, Yarnell J, Zamorano JL (2007): European guidelines on cardiovascular disease prevention in clinical practice: executive summary. European Heart Journal 28, 2375-2414.
    20. Groszek G, Bajek A, Bis A, Nowak-Krol A, Bednarski M, Siwek A, Filipek B (2010): Synthesis and adrenolytic activity of new propanolamines. Molecules 15, 3887-3904. Go to original source... Go to PubMed...
    21. Janota T (2012): Esmolol - position in current clinical practice (in Czech). Remedia 22, 150-153.
    22. Kamensky G, Murin J (2009): Cardiovascular diseases - the biggest threat (in Slovak). White book, Slovak cardiologic society. Bratislava. 11-64. Available at http://www.tvojesrdce.sk/article/16-kardiovaskularne-ochorenianajvaecsia-hrozba-biela-kniha (Accessed August 27, 2015).
    23. Keckesova S, Sedlarova E, Csollei J, Mokry P, Vanco J, Vanko M (2008a): Synthesis, identification and physicochemical properties of novel potential ultrashort-acting beta-adrenergic blockers. Acta Facultatis Pharmaceuticae Universitatis Comenianae 55, 122-128.
    24. Keckesova S, Sedlarova E, Csollei J, Mokry P (2008b): Study of physicochemical properties of potential ultrashort acting beta-blockers. Chemicke Listy 102, 179-264.
    25. Kodl M, Antosova D, Benes C, Csemy L, Castkova J, Fabianova K, Filipova V, Grolmusova L, Jakubu V, Janatova H, Jindrak V, Kazamrova H, Kebza V, Kernova V, Kozakova J, Kratenova J, Kriz B, Krizova P, Kyncl J, Lexova P, Lustigova M, Mackova B, Maly M, Marejkova M, Mravcik V, Necas V, Nejedla M, Prochazka B, Puklova V, Ruprich J, Sovinova H, Urban P, Urbankova P, Vit M, Zakoucka H, Zemanova D, Zemanova I, Ziegler M, Zimenova I, Zvadova Z, Zejglicova K (2014): Report on the Health of the Czech population (in Czech). The Ministry of Health of the Czech Republic, Praha. Available at http://www.mzcr.cz/verejne/dokumenty/zprava-o-zdravi-obyvatelceske-republiky2014-_9420_3016_5.html (Accessed August 27, 2015).
    26. Lefkowitz RJ, Shenoy SK (2005): Transduction of receptor signals by beta-arrestins. Science 308, 512-517. Go to original source... Go to PubMed...
    27. Marik PE, Varon J (2009): Perioperative hypertension: a review of current and emerging therapeutic agents. Journal of Clinical Anesthesia 21, 220-229. Go to original source... Go to PubMed...
    28. Mokry P, Koliskova M, Pavlica J, Tengler J, Csollei J (2009): Stereoselective synthesis of arylkarbonyloxyaminopropanoles (in Czech). Synthesis and analysis of drugs 38, Hradec Kralove. 91, 153 pp. Available at http://www.faf.cuni.cz/Verejnost/Konference/Archiv/2009/Synteza-aanalyza-leciv-2009/ (Accessed October 7, 2015).
    29. Potter PM, Wadkins RM (2006): Carboxylesterases - detoxifying enzymes and targets for drug therapy. Current Medicinal Chemistry 13, 1045-1054. Go to original source... Go to PubMed...
    30. Rovny I (2012): Report on the health status of the population of the Slovak Republic for the years 2009-2011. Available at www.uvzsr.sk/docs/info/podpora/Sprava_o_ zdravotnom_stave_obyvatelstva_SR_za_roky_2009_2011. pdf (Accessed June 15, 2017).
    31. Rovny I (2015): Report on the health status of the population of the SR for the years 2012-2014. Available at https://lt.justice.gov.sk/Attachment/SoZSO%20vlastn_materi%87l.pdf?instEID=-1&attEID=81571&docEID=442770&matEID=8457〈EID=1&tStamp=20150819080609483 (Accessed June 15, 2017).
    32. Spinar J, Vitovec J (2006): The combination therapy of heart failure (in Czech). Remedia 16, 244-251.
    33. Styk J (ed.) (2013): Brief Pathophysiology of Cardiovascular System (in Slovak). 2nd edn. Slovak Medical University in Bratislava, Faculty of Medicine. 95.
    34. Tengler J, Stropnicky O (2014): Drugs with controlled metabolism and drug design (in Czech). Chemicke Listy 108, 25-31.
    35. Tengler J, Kapustikova I, Pesko M, Govender R, Keltosova S, Mokry P, Kollar P, O'Mahony J, Coffey A, Kralova K, Jampilek J (2013a): Synthesis and biological evaluation of 2-hydroxy-3-[(2-aryloxyethyl)amino]propyl-4-[(alkoxycarbonyl) amino]benzoates. The Scientific World Journal, doi: 10.1155/2013/274570. Go to original source... Go to PubMed...
    36. Tengler J, Kapustikova I, Stropnicky O, Mokry P, Oravec M, Csollei J, Jampilek J (2013b): Synthesis of new (arylcarbonyloxy) aminopropanol derivatives and the determination of their physico-chemical properties. Central European Journal of Chemistry 11, 1757-1767. Go to original source...
    37. Varon J (2008): Treatment of acute severe hypertension current and newer agents. Drugs 68, 283-297. Go to original source... Go to PubMed...
    38. Wada Y, Aiba T, Tsujita Y, Itoh H, Wada M, Nakajima I, Ishibashi K, Okamura H, Miyamoto K, Noda T, Sugano Y, Kanzaki H, Anzai T, Kusano K, Yasuda S, Horie M, Ogawa H (2016): Practical applicability of landiolol, an ultra-short-acting β1-selective blocker, for rapid atrial and ventricular tachyarrhythmias with left ventricular dysfunction. Journal of Arrhythmia 32, 82-88. Go to original source... Go to PubMed...
    39. Wenquan N, Yue Q (2016): A meta-analysis of randomized controlled trials assessing the impact of beta-blockers on arterial stiffness, peripheral blood pressure and heart rate. International Journal of Cardiology 218, 109-117. Go to original source... Go to PubMed...
    40. Wolf J, Drozdowski J, Czechowicz K, Winklewski PJ, Jassem E, Kara T, Somers VK, Narkiewicz K (2016): Effect of beta-blocker therapy on heart rate response in patients with hypertension and newly diagnosed untreated obstructive sleep apnea syndrome. International Journal of Cardiology 202, 67-72. Go to original source... Go to PubMed...
    41. Yamakage M, Iwasaki S, Jeong S, Satoh J, Namiki A (2009): Beta-1 selective adrenergic antagonist landiolol and esmolol can be safely used in patients with airway hyperreactivity. Heart and Lung 38, 47-55. Go to original source... Go to PubMed...
    42. Zicha S, Tsuji Y, Shiroshita-Takeshita S, Nattel S (2006): β-blockers as antiarrhythmic agents. Handbook of Experimental Pharmacology 171, 235-262. Go to original source...

    This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY NC 4.0), which permits non-comercial use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.


    Return to the content